Biopsy Guidance Systems Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Biopsy guidance systems combine imaging hardware, software, and often robotic or stereotactic components to direct needles and instruments precisely to suspicious lesions. The category spans MRI-guided, ultrasound-guided, CT-guided, and stereotactic systems used across breast, prostate, lung, liver, and other solid-tumor applications. In 2025 the global market is valued at approximately USD 1.31 billion, with most projections pointing to expansion into the USD 2.1-2.8 billion range by 2030-2034 at a compound annual growth rate of around 6-7%.

• •Global valuation of about USD 1.31 billion in 2025, with forecasts converging near USD 2.1-2.8 billion by the early-to-mid 2030s.
• •Growth driven primarily by cancer diagnostics, where image-guided sampling is increasingly standard of care.
• •Modalities in scope include MRI-guided, ultrasound-guided, CT-guided, and stereotactic biopsy platforms.

The principal engine is the global rise in cancer incidence and screening volumes, which directly increases demand for accurate tissue sampling. Technological improvements in real-time imaging, instrument tracking, and software fusion of ultrasound with MRI or CT are making biopsies faster, safer, and more reliable. Hospitals and outpatient centers are also investing in minimally invasive diagnostic equipment to reduce procedure times, improve patient comfort, and lower overall cost of care.

• •Rising global cancer burden and expanded screening programs are lifting procedure volumes year over year.
• •Advances in imaging resolution, image fusion, and robotic needle positioning are expanding clinical indications.
• •Reimbursement coverage for image-guided biopsy in major markets is supporting broader hospital adoption.

By product, MRI-guided biopsy is typically the largest and fastest-growing segment, followed by stereotactic and ultrasound-guided systems, with CT-guided platforms representing a smaller but stable share. North America holds the leading share of revenue, supported by installed imaging infrastructure and high screening rates, while Europe contributes the second-largest region. Asia-Pacific is the fastest-growing regional market, driven by healthcare investment in China, India, Japan, and Southeast Asia.

• •MRI-guided systems lead by revenue, with stereotactic and ultrasound-guided systems as significant adjacent segments.
• •North America leads regional revenue, followed by Europe, with Asia-Pacific expanding the quickest.
• •End-use is dominated by hospitals, with ambulatory surgical centers and diagnostic imaging clinics growing in share.

What are the recent trends and outlook?

AI-assisted lesion detection, automated needle trajectory planning, and tighter integration with robotic platforms are emerging as defining features of next-generation systems. Vendors are also pushing toward outpatient and office-based workflows, where smaller footprint ultrasound and fusion platforms can replace room-based systems for certain indications. Through the remainder of the decade, expect sustained mid-single-digit growth as cancer diagnostics volumes rise and as AI-enabled, minimally invasive biopsy becomes a routine part of oncology pathways.

• •AI-based lesion detection and planning is moving from optional feature to standard differentiator.
• •Robotic bronchoscopy and robotic-assisted soft-tissue biopsy are opening new high-growth subsegments.
• •Outlook through 2030 is for continued mid-single-digit annual growth, with the market likely to more than double from its 2025 base.